Point Biopharma Global

POINT Biopharma Global, Inc. is a precision oncology company, which engages in the development and commercialization of radiopharmaceuticals for the treatment of cancer. It offers CanSEEK, a technology which aims to minimize radiopharmaceutical toxicity caused by off-target delivery by only activating a radiopharmaceuticals' targeting moiety. The company was founded by Joe McCann and Neil E. Fleshner on April 15, 2020 and is headquartered in Indianapolis, IN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization.

INDIANAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the third quarter ended September 30, 2022, and provided an update on business highlights, including the announcement of a strategic collaboration and exclusive license agreements with Lantheus Holdings Inc. (NASDAQ: LNTH) for the commercialization of PNT2002 & PNT2003.

POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings

Collaboration pairs POINT's expertise in next generation radioligand development and manufacturing with Lantheus' commercial leadership in PSMA PET and radiopharmaceuticals

Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003

The average of price targets set by Wall Street analysts indicates a potential upside of 212.4% in POINT Biopharma Global Inc. (PNT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in POINT Biopharma Global Inc. (PNT)? Wall Street Analysts Think 212%

POINT Biopharma (PNT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for POINT Biopharma (PNT)

The consensus price target hints at a 235.3% upside potential for POINT Biopharma Global Inc. (PNT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think POINT Biopharma Global Inc. (PNT) Could Surge 235%: Read This Before Placing a Bet

PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225

POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EANM's Annual Congress

INDIANAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced the closing of its previously announced underwritten public offering of 13,900,000 shares of Common Stock at a public offering price of $9.00 per share. The gross proceeds to the Company from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $125 million.

POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock

The market didn't react well to news of the biotech's latest financing effort.

Why Point Biopharma Global Stock Got Crushed Today

INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced the pricing of its public offering of 13,900,000 shares of Common Stock at a public offering price of $9.00 per share. The gross proceeds to the Company from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $125 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 2,085,000 shares of its Common Stock. All of the shares to be sold in the offering are to be sold by POINT. The offering is expected to close on or about September 16, 2022, subject to customary closing conditions.

POINT Biopharma Prices Public Offering of Common Stock

INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced that it has commenced an underwritten public offering of its common stock. In addition, POINT expects to grant the underwriters a 30-day option to purchase up to an additional 15% of its common stock being sold in the offering at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in this offering will be sold by POINT. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or the actual size or terms of the proposed offering.

POINT Biopharma Announces Proposed Public Offering of Common Stock

Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including:

POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022

Short-sellers appear to be pouncing on an upcoming scientific presentation.

Why Point Biopharma Global Stock Is Getting Crushed Today

Poster #1400P will be presented on Sunday, September 11 by Dr. Aaron R. Hansen Poster #1400P will be presented on Sunday, September 11 by Dr. Aaron R. Hansen

POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial

In advance of the abstract publication, POINT hosted an educational webinar entitled “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”

POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial

Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release

POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights

The event will prepare investors for the release of SPLASH's lead-in cohort efficacy data later this year by providing an overview of SPLASH's trial design.

POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022

Mr. Horvath will lead the commercialization of POINT's pipeline. He brings over a decade of experience in pharmaceutical commercialization, most recently as the VP and Head of Prostate Cancer Radioligand Therapy Franchise at Advanced Accelerator Applications (a Novartis Company)

POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial

A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004's Phase 1 therapeutic trial using 68 Ga-PNT6555 for imaging and 177 Lu-PNT6555 for therapy

POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program

POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled.

POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update

Clinical doses continue to be manufactured and shipped from the Company's Indianapolis, Indiana facility Clinical doses continue to be manufactured and shipped from the Company's Indianapolis, Indiana facility

POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial

POINT's PNT6555 is a potent and specific inhibitor of Fibroblast Activation Protein (FAP), a phase 1 therapeutic trial using 68 Ga-PNT6555 for imaging and 177 Lu-PNT6555 for therapy is planned for summer 2022

POINT Biopharma to Present on its Pan-Cancer FAP-Alpha Targeted Program at the AACR Annual Meeting

Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial

POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update

POINT's industry-leading radioisotope supply chain enabled company to avoid delays POINT's industry-leading radioisotope supply chain enabled company to avoid delays

POINT Biopharma Confirms No Delays to SPLASH Trial Due to Recent Global Lutetium Supply Interruption

Learn what “PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied” means in the context of radiopharmaceuticals

News for Point Biopharma Global Stock (PNT)